Key Takeaways Hologic's Molecular Diagnostics grew 7.8% in Q2 despite pressure from lost HIV testing revenues. Excluding USAID cuts, molecular sales would have seen low double-digit growth, per HOLX management. HOLX's molecular growth is fueled by innovation, including high-throughput vaginitis assays.Hologic’s (HOLX) Molecular Diagnostics business posted a 7.8% (excluding COVID-19-related sales) growth in the second quarter of fiscal 2025, although results did not reflect its full potential.The performan ...

Core Insights - The women's health diagnostics market is projected to grow at a compound annual growth rate (CAGR) of 9.25% through 2030, driven by technological advancements and increased healthcare expenditures [1] - Hologic and Quest Diagnostics are key players in the women's health sector, each with distinct specializations and market strategies [2][3] Hologic Overview - Hologic, with a market cap of $12.10 billion, focuses on advanced diagnostics, medical imaging, and surgical products, benefiting from multiple growth drivers across its global franchises [2][4] - Key products include Aptima and Panther Fusion assays, which are experiencing strong double-digit growth due to rising awareness and reimbursement in the U.S. vaginitis market [4] - The Genius Digital Diagnostics System, the first FDA-cleared digital cytology system for cervical cancer screening, is gaining traction, although international sales were impacted by external factors [5] - Hologic's mammography products maintain leading market shares, with recurring service revenues increasing by 12% year-over-year [6] - The Surgical business is performing well, but macroeconomic challenges, including tariffs, are expected to impact manufacturing costs significantly [7] Quest Diagnostics Overview - Quest Diagnostics, with a market cap of $19.12 billion, is experiencing strong growth in Women's and Reproductive Health, driven by prenatal and hereditary genetic testing [2][8] - The company launched a new self-collection solution for HPV cervical cancer screening, enhancing its diagnostic offerings [8] - Other clinical areas, including cardiometabolic and oncology, also reported double-digit growth, contributing to a 12% year-over-year revenue increase [9][10] - Quest completed eight acquisitions in 2024, positively impacting sales and adjusted operating income, with a notable growth in adjusted EPS of 8.3% [11] - The company is leveraging automation and AI to improve productivity, while maintaining its revenue and EPS guidance despite rising debt levels [12] Financial Estimates and Performance - Hologic's fiscal 2025 sales and EPS estimates suggest a year-over-year improvement of 1.2% and 3.2%, respectively, with mixed movements in bottom-line estimates [13] - Quest Diagnostics' 2025 sales and EPS estimates indicate a year-over-year improvement of 9.2% and 8.6%, respectively, with analysts showing increased optimism [13] - Hologic's shares have decreased by 31.6% over the past six months, while Quest Diagnostics has gained 4.9% [14] Valuation Comparison - Hologic is trading at a forward price-to-sales (P/S) multiple of 2.87X, while Quest Diagnostics is at 1.75X, both below their respective industry averages [16] - Both companies have a Value score of B, indicating potential for long-term stability [16] Investment Outlook - Hologic's diversified revenue model and international prospects suggest potential for long-term stability despite near-term challenges [17] - Quest Diagnostics shows strong growth opportunities in women's health, with favorable stock performance and upward analyst revisions making it a compelling investment [18]

Hologic (HOLX) 2025 Conference May 20, 2025 09:30 AM ET Speaker0 And welcome to the RBC Capital Markets twenty twenty five Global Healthcare Conference. I'm Connor McNamara, the life science tools and diagnostics analyst with RBC. It's my pleasure to welcome Hologic, and with me today is Carleen Overton, the CFO of Hologic. Carleen, thanks for joining us. Speaker1 Thanks for having me. Speaker0 I'd like to kick it off, and and I'm sorry to make this open ended, but just wanted to give you a chance to you kn ...

Hologic (HOLX) Q2 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Hologic's Second Quarter Fiscal twenty twenty five Earnings Conference Call. My name is Rachel, and I'm your operator for today's call. Today's conference is being recorded. All lines have been placed on mute. I would now like to introduce Mike Watts to begin the call. Speaker1 Thank you, Rachel. Good afternoon and thank you for joining Hologic's second quarter fiscal twenty twenty five earnings call. With ...

Hologic (HOLX) Q2 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Michael Watts - Vice President of Investor Relations & Corporate CommunicationsStephen MacMillan - Chairman, CEO & PresidentEssex Mitchell - Chief Operating OfficerKarleen Oberton - CFOPuneet Souda - Senior MDAnthony Petrone - Managing DirectorJoseph Stringer - Managing Director, Equity ResearchLu Li - Healthcare Equity Research, DirectorCasey Woodring - Vice President - Equity ResearchAvery Kriss - Equity Research AssociateA ...